Haemodialysis and peritoneal dialysis patients have severely impaired post-occlusive skin forearm vasodilatory response assessed with laser speckle contrast imaging.
end-stage renal disease
endothelial dysfunction
haemodialysis
laser speckle contrast imaging (LSCI)
peritoneal dialysis
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
18
05
2020
entrez:
7
5
2021
pubmed:
8
5
2021
medline:
8
5
2021
Statut:
epublish
Résumé
Endothelial dysfunction is associated with cardiovascular events and mortality in various disease states, including end-stage renal disease (ESRD). Novel technological approaches have emerged for real-time assessment of endothelial reactivity. This study examined skin microcirculation using laser speckle contrast imaging (LSCI) before and after arterial occlusion in ESRD patients undergoing haemodialysis (HD) or peritoneal dialysis (PD). The 38 HD patients were matched in a 1:1 ratio with 38 PD patients (for age, sex and dialysis vintage) and 38 controls (for age and sex). Skin microvascular reactivity parameters assessed with LSCI included baseline perfusion, occlusion perfusion and peak perfusion during post-occlusive reactive hyperaemia (PORH); time to peak perfusion; proportional change from baseline to peak perfusion; baseline and peak cutaneous vascular conductance (CVC); proportional change from baseline to peak CVC and amplitude of the PORH response (i.e. the difference between peak and baseline CVC). Baseline perfusion [HD: 46.97 ± 14.6; PD: 49.32 ± 18.07; controls: 42.02 ± 11.94 laser specle perfusion units (LSPU), P = 0.097] and peak post-occlusion perfusion (104.77 ± 28.68 versus 109.04 ± 40.77 versus 116.96 ± 30.96 LSPU, P = 0.238) did not differ significantly between groups. However, the post-occlusive vascular response was completely different since the proportional increase from baseline to peak perfusion (HD: 133 ± 66; PD: 149 ± 125; controls: 187 ± 61%, P = 0.001) was significantly lower in ESRD patients and time to peak response was lower in HD but similar in PD patients compared with controls (HD: 7.24 ± 6.99; PD: 10.68 ± 9.45; controls: 11.11 ± 5.1 s, Kruskal-Wallis P = 0.003; pairwise comparisons: HD versus controls, P = 0.002; HD versus PD, P = 0.154; PD versus controls, P = 0.406). ESRD patients also had lower levels of peak CVC, indicating the maximum capillary recruitment (HD: 1.05 ± 0.3; PD: 1.07 ± 0.44; controls: 1.57 ± 0.52 LSPU/mmHg, P < 0.001), lower proportional increase of CVC at peak (P < 0.001) and lower amplitude of the PORH response, a measure of the difference between baseline and maximum capillary recruitment (P = 0.001). Using this novel non-invasive technology, endothelial post-occlusive forearm skin vasodilatory response was found to be similar between HD and PD patients and significantly impaired compared with controls. Future studies are needed to assess the prognostic implications of this microcirculatory functional defect.
Sections du résumé
BACKGROUND
BACKGROUND
Endothelial dysfunction is associated with cardiovascular events and mortality in various disease states, including end-stage renal disease (ESRD). Novel technological approaches have emerged for real-time assessment of endothelial reactivity. This study examined skin microcirculation using laser speckle contrast imaging (LSCI) before and after arterial occlusion in ESRD patients undergoing haemodialysis (HD) or peritoneal dialysis (PD).
METHODS
METHODS
The 38 HD patients were matched in a 1:1 ratio with 38 PD patients (for age, sex and dialysis vintage) and 38 controls (for age and sex). Skin microvascular reactivity parameters assessed with LSCI included baseline perfusion, occlusion perfusion and peak perfusion during post-occlusive reactive hyperaemia (PORH); time to peak perfusion; proportional change from baseline to peak perfusion; baseline and peak cutaneous vascular conductance (CVC); proportional change from baseline to peak CVC and amplitude of the PORH response (i.e. the difference between peak and baseline CVC).
RESULTS
RESULTS
Baseline perfusion [HD: 46.97 ± 14.6; PD: 49.32 ± 18.07; controls: 42.02 ± 11.94 laser specle perfusion units (LSPU), P = 0.097] and peak post-occlusion perfusion (104.77 ± 28.68 versus 109.04 ± 40.77 versus 116.96 ± 30.96 LSPU, P = 0.238) did not differ significantly between groups. However, the post-occlusive vascular response was completely different since the proportional increase from baseline to peak perfusion (HD: 133 ± 66; PD: 149 ± 125; controls: 187 ± 61%, P = 0.001) was significantly lower in ESRD patients and time to peak response was lower in HD but similar in PD patients compared with controls (HD: 7.24 ± 6.99; PD: 10.68 ± 9.45; controls: 11.11 ± 5.1 s, Kruskal-Wallis P = 0.003; pairwise comparisons: HD versus controls, P = 0.002; HD versus PD, P = 0.154; PD versus controls, P = 0.406). ESRD patients also had lower levels of peak CVC, indicating the maximum capillary recruitment (HD: 1.05 ± 0.3; PD: 1.07 ± 0.44; controls: 1.57 ± 0.52 LSPU/mmHg, P < 0.001), lower proportional increase of CVC at peak (P < 0.001) and lower amplitude of the PORH response, a measure of the difference between baseline and maximum capillary recruitment (P = 0.001).
CONCLUSIONS
CONCLUSIONS
Using this novel non-invasive technology, endothelial post-occlusive forearm skin vasodilatory response was found to be similar between HD and PD patients and significantly impaired compared with controls. Future studies are needed to assess the prognostic implications of this microcirculatory functional defect.
Identifiants
pubmed: 33959270
doi: 10.1093/ckj/sfaa136
pii: sfaa136
pmc: PMC8087130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1419-1427Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Braz J Med Biol Res. 2016 Sep 01;49(10):e5541
pubmed: 27599202
Circulation. 2003 Oct 28;108(17):2093-8
pubmed: 14530195
Kidney Blood Press Res. 2013;38(1):72-82
pubmed: 24577239
Microvasc Res. 2011 Nov;82(3):326-32
pubmed: 21803051
Clin J Am Soc Nephrol. 2011 Aug;6(8):2009-15
pubmed: 21784831
Circulation. 2007 Mar 13;115(10):1285-95
pubmed: 17353456
Clin J Am Soc Nephrol. 2011 Nov;6(11):2620-7
pubmed: 21940841
Int J Mol Sci. 2019 Jul 14;20(14):
pubmed: 31337127
Circ Res. 2016 Feb 19;118(4):620-36
pubmed: 26892962
Nature. 1993 Apr 29;362(6423):801-9
pubmed: 8479518
Circulation. 2004 Jun 1;109(21):2507-10
pubmed: 15136499
J Biomed Opt. 2019 Aug;24(8):1-11
pubmed: 31385481
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
pubmed: 11788217
Microvasc Res. 2011 Nov;82(3):439-42
pubmed: 21784084
Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2687-96
pubmed: 15297253
Nephrol Dial Transplant. 2001 Oct;16(10):1968-71
pubmed: 11572879
Microvasc Res. 2011 Jul;82(1):88-91
pubmed: 21439303
Int J Nephrol Renovasc Dis. 2020 Mar 27;13:45-51
pubmed: 32273746
Nephrol Dial Transplant. 2010 Dec;25(12):4031-41
pubmed: 20466676
Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):109-14
pubmed: 23073231
Microvasc Res. 2010 Dec;80(3):505-11
pubmed: 20542492
J Diabetes Complications. 2017 Apr;31(4):753-757
pubmed: 28089343
J Biomed Opt. 2010 Jan-Feb;15(1):011109
pubmed: 20210435
J Am Coll Surg. 2017 Sep;225(3):395-402
pubmed: 28669885
BMC Nephrol. 2016 Jul 13;17(1):82
pubmed: 27412615
J Hypertens. 2005 Feb;23(2):233-46
pubmed: 15662207
Kidney Int. 2004 Feb;65(2):700-4
pubmed: 14717944
Muscle Nerve. 2007 Nov;36(5):595-614
pubmed: 17623856
Circulation. 2002 Aug 6;106(6):653-8
pubmed: 12163423
J Am Soc Nephrol. 2004 Aug;15(8):1983-92
pubmed: 15284284
J Biomed Opt. 1996 Apr;1(2):174-9
pubmed: 23014683
Physiol Meas. 2019 Jul 01;40(6):065002
pubmed: 31071696
J Clin Endocrinol Metab. 2007 Feb;92(2):379-85
pubmed: 17118997
Kidney Int. 2006 Jul;70(1):157-64
pubmed: 16710351
Microvasc Res. 2015 Sep;101:82-5
pubmed: 26142117
J Hypertens. 2011 Aug;29(8):1569-76
pubmed: 21720275
Circulation. 2012 Aug 7;126(6):753-67
pubmed: 22869857
J Clin Hypertens (Greenwich). 2012 Apr;14(4):198-205
pubmed: 22458740
Hypertension. 2016 Oct;68(4):913-20
pubmed: 27550915
J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S83-8
pubmed: 15938042
Front Neuroenergetics. 2010 Sep 15;2:
pubmed: 20941368
Neurosurg Focus. 2009 Oct;27(4):E11
pubmed: 19795950
Lancet. 2001 Dec 22-29;358(9299):2113-7
pubmed: 11784625
Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640
pubmed: 28340239
Hypertension. 2011 Apr;57(4):846-51
pubmed: 21300663